Biohaven Ltd.
$10.81
+6.7%Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.6).
Valuation inputs: P/E -1.6, earnings yield N/A, momentum +6.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -14.2%, ROIC -2.2%).
Profitability stack: net margin 0.0%, ROE -14.2%, ROIC -2.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +88.5%, momentum +6.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Biohaven Ltd. Market vs Earnings Trajectory
Loading price and EPS data...
Biohaven Ltd. Fair Value Envelope
No Revenue Data
BHVN has not reported any revenue values in the available annual periods.
Biohaven Ltd. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
BHVN has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
BHVN has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
BHVN has not reported any net profit margin values in the available annual periods.
Biohaven Ltd. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Biohaven Ltd. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Biohaven Ltd. Street Expectations Map
Wall Street analysts project that BHVN stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.60, with estimates ranging from a low of 10.00 to a high of 23.00.
The consensus 1-year price target stands at 17.60, with estimates ranging from a low of 10.00 to a high of 23.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Biohaven Ltd. Insider Positioning
During the last 12 months, insiders have purchased $30.64M worth of BHVN shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
4.1M
30.64M
0
0.00
+30.6M
+$30.64M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Childs John W
Director
$25.00M
Bailey Gregory
Director
$3.00M
Coric Vlad
Director, Officer: Chief Executive Officer
$2.50M
Clark George C.
Officer: Vp, Chief Accounting Officer
$145K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $30.64M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
BHVN has not reported any dividend yield values in the available annual periods.
bhvn Dividend History
Learning Layer
Related Guides
Build conviction on BHVN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.